Baseline characteristics for INFRONT 3: A Phase 3 double blind, placebo[...]
Notification Letter and Reply Form to Non registered Shareholders[...]
05/24/2022 | Press release | Distributed by Public on 05/24/2022 05:22
Please select the service you want to use:
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact